L-Nucleic Acid SDF-1 Binding for Cell Migration Control
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for diseases such as diabetic nephropathy, autoimmune disorders, and cancer lack effective methods to inhibit the migration of leukocytes and stem cells, which contributes to inflammation and tissue damage.
Innovation Solution
The use of L-nucleic acid molecules binding to SDF-1 to influence cell migration, specifically mobilizing progenitor cells, stem cells, and immune cells into the peripheral blood, while inhibiting the interaction between SDF-1 and its receptor to reduce leukocyte infiltration in tissues.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current treatments are used for diseases such as diabetic nephropathy, autoimmune disorders, and cancer, then general disease management is provided, but effective inhibition of leukocyte and stem cell migration is not achieved, leading to continued inflammation and tissue damage
Solution Approach 1:
The patent introduces L-nucleic acid molecules as intermediary substances that specifically bind to SDF-1, blocking its interaction with CXCR4 receptors. This intermediary approach prevents the harmful migration signal transmission without directly attacking the cells, thereby reducing inflammation and tissue damage while managing the underlying disease conditions
Solution Approach 2:
The invention extracts and targets the specific migratory signal pathway (SDF-1/CXCR4) that contributes to harmful cell infiltration. By isolating and blocking this specific signal, the treatment removes the harmful migratory drive without affecting other essential cellular functions, thereby reducing inflammation while maintaining disease management
2Object-affected harmful factors
If L-nucleic acid molecules binding to SDF-1 are used to inhibit cell migration, then leukocyte infiltration in tissues is reduced, but the ability to mobilize beneficial progenitor cells and stem cells into peripheral blood must be maintained for therapeutic use
Solution Approach 1:
The L-nucleic acid molecules exhibit local quality by differentiating between harmful and beneficial cell migration contexts. The same SDF-1 binding mechanism achieves opposite therapeutic effects: it blocks harmful leukocyte infiltration into tissues while simultaneously facilitating the mobilization of beneficial progenitor cells and stem cells into peripheral blood, depending on the local physiological context and cell type
Solution Approach 2:
The invention changes the parameter of cell migration control by introducing L-nucleic acid molecules that bind to SDF-1 with specific affinity characteristics. This parameter change in binding affinity and selectivity allows differential modulation of migration for different cell types, enabling both reduced leukocyte infiltration and enhanced mobilization of therapeutic cells
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach effectively mobilizes beneficial cells into the bloodstream for therapeutic use while reducing inflammatory cell accumulation in tissues, offering potential treatments for diabetic nephropathy, autoimmune diseases, and cancer by modulating cell migration and infiltration.
Implementation Method 1
L-nucleic acid molecule binding to SDF-1
Data Source
Figure 1
Figure 1
Figure 2A
AI summary
The present invention is related to a nucleic acid molecule binding to SDF-1, whereby the nucleic acid molecule influences migration of cells.